{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:15:09Z","timestamp":1779250509997,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eprac.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:23:29Z","timestamp":1752607409000},"page":"1560-1567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison Between Alendronate and Denosumab in Preventing Bone Loss and Lowering Fracture Risk Related to Adjuvant Endocrine Therapy for Breast Cancer: Real-World Data From a Third-Level Center Experience"],"prefix":"10.1016","volume":"31","author":[{"given":"Claudio","family":"Gianfelice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Firmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmaria","family":"Salvio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4945-6437","authenticated-orcid":false,"given":"Alessandro","family":"Ciarloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Ferroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Silvetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirco","family":"Pistelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Agostinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Balercia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberta","family":"Giacchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eprac.2025.07.004_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.004_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004","volume":"23","author":"Winer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eprac.2025.07.004_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1249160","article-title":"Aromatase inhibitors: the journey from the state of the art to clinical open questions","volume":"13","author":"Generali","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.004_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.eprac.2022.12.003","article-title":"Managing bone health in breast cancer","volume":"29","author":"Kearns","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2025.07.004_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","article-title":"Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study","volume":"94","author":"Wilson","year":"2018","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.004_bib6","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s12325-021-01812-9","article-title":"Bone health outcomes from the international, multicenter, randomized, phase 3, placebo-controlled D-CARE study assessing adjuvant denosumab in early breast cancer","volume":"38","author":"Coleman","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2025.07.004_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bone.2018.06.007","article-title":"Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial","volume":"114","author":"Kyvernitakis","year":"2018","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.004_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","article-title":"Guidelines for the diagnosis, prevention and management of osteoporosis","volume":"68","author":"Rossini","year":"2016","journal-title":"Reumatismo"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.004_bib9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eprac.2025.07.004_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2018.04.006","article-title":"Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM)","volume":"99","author":"Gori","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.004_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jbmr.3886","article-title":"Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates","volume":"35","author":"Pineda-Moncus\u00ed","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.004_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.004_bib13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ecl.2024.08.002","article-title":"Prevention and management of denosumab discontinuation rebound fractures","volume":"53","author":"Jain","year":"2024","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.eprac.2025.07.004_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1297950","article-title":"The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors","volume":"14","author":"Galvano","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.004_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40618-023-02174-5","article-title":"Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors","volume":"47","author":"Antonini","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.004_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/ejendo\/lvae086","article-title":"Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies","volume":"191","author":"Birtolo","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.004_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s00223-022-01011-w","article-title":"Real-world effectiveness of denosumab and bisphosphonates on risk of vertebral fractures in women with breast cancer undergoing treatment with aromatase inhibitors","volume":"111","author":"Mazziotti","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.004_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2416","article-title":"Comparison of risk of osteoporotic fracture in denosumab vs alendronate treatment within 3 years of initiation","volume":"2","author":"Pedersen","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.004_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/jbmr\/zjae079","article-title":"Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis","volume":"39","author":"Curtis","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.004_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.004_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","article-title":"Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis","volume":"16","author":"Migliorini","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.004_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.afos.2016.03.003","article-title":"Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis","volume":"2","author":"Benjamin","year":"2016","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.eprac.2025.07.004_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bone.2014.12.062","article-title":"Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS)","volume":"75","author":"Di Gregorio","year":"2015","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.004_bib24","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/jbmr.499","article-title":"Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study","volume":"26","author":"Hans","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.07.004_bib25","series-title":"Bone Regulators and Osteoporosis Therapy. Vol 262. Handbook of Experimental Pharmacology","first-page":"397","article-title":"Osteoporosis therapeutics 2020","author":"Kocijan","year":"2020"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.004_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.004_bib27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.004_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12018-020-09274-3","article-title":"Bone metabolism in SARS-CoV-2 disease: possible osteoimmunology and gender implications","volume":"18","author":"Salvio","year":"2020","journal-title":"Clinic Rev Bone Miner Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.004_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12020-012-9696-x","article-title":"Skeletal and extraskeletal actions of denosumab","volume":"42","author":"Sinningen","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2025.07.004_bib30","first-page":"107","article-title":"Role of oxidative stress and the microenvironment in breast cancer development and progression","volume":"Vol 119","author":"Jezierska-Drutel","year":"2013"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.004_bib31","article-title":"Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis","volume":"2024","author":"Adams","year":"2024","journal-title":"Cochrane Breast Cancer Group, ed. Cochrane Database of Systematic Reviews"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:37:21Z","timestamp":1765967841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25009620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1530891X25009620"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.004","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison Between Alendronate and Denosumab in Preventing Bone Loss and Lowering Fracture Risk Related to Adjuvant Endocrine Therapy for Breast Cancer: Real-World Data From a Third-Level Center Experience","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}